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Somatostatin (SST14) is strongly related to Alzheimer’s disease (AD), as its levels decline 
during aging, it regulates the proteolytic degradation of the amyloid beta peptide (Aβ), and it 
binds to Aβ oligomers in vivo. Recently, the 3D structure of a membrane-associated β-sheet 
pore forming tetramer (βPFOAβ(1-42) tetramer) has been reported. Here we show that SST14 
binds selectively to the βPFOAβ(1-42) tetramer with an a KD of ~40 µM without binding to 
monomeric Aβ(1-42). Specific NMR chemical shift perturbations, observed during titration of 
SST14, define a binding site in the βPFOAβ(1-42) tetramer and are in agreement with a 2:1 
stoichiometry determined by both native MS and ITC. These results enabled us to perform 
driven docking and model the binding mode for the interaction. The present study provides 
additional evidence on the relation between SST14 and the amyloid cascade, as well as 
positions the βPFOAβ(1-42) tetramer as a relevant aggregation form of Aβ and as a potential target 
for AD.  
 3 
Introduction 
Increased levels of amyloid beta peptide (Aβ) and deposition of amyloid fibrils in neuronal 
cells constitute a critical part of the etiopathogenesis in Alzheimer’s disease (AD).1,2 Aβ 
originates from the sequential cleavage of the amyloid precursor protein (APP) by the β-
secretase in the extracellular space and the 𝛾-secretase in the transmembrane domain.3 In 
solution, this hydrophobic peptide aggregates in a nucleation-dependent manner into soluble 
oligomers4 that gradually increase in molecular-weight until insoluble fibrils are formed 5-8. 
The presence of amyloid fibrils in the extracellular space has inevitably drawn research interest 
in Aβ peptides to this location. However, the fact that Aβ’s origin lies within APP, a 
transmembrane protein,9 together with numerous reported work of Aβ interacting with the 
cellular membrane,10-15 strongly suggests this environment as an alternative location for Aβ 
accumulation and aggregation.  
We have previously studied the aggregation of Aβ within detergent micelles to mimic the 
membrane environment and reported the preparation16 and the three-dimensional (3D) 
structure17 of a membrane-associated β-sheet pore forming tetramer (βPFOAβ(1-42) tetramer) 
(Figure S1). Interestingly, the formation of this oligomer was specific for Aβ(1-42), the variant 
most related to AD but not Aβ(1-40) which is the variant most abundant in the brain. βPFOAβ(1-
42) tetramer comprises a β-sheet core formed by six β-strands. Molecular dynamics showed that 
when βPFOAβ(1-42) tetramer incorporated into lipid bilayers and water molecules were able to 
permeate the membrane through the hydrophilic edges of the β-sheet core tetramer. This work 
not only represented the resolution of the first 3D structure of an Aβ oligomer but also the 
definition of a new mechanism of membrane disruption that could explain the neurotoxic 
activity of Aβ oligomers in the context of AD.  
The screening of potential interactors constitutes an essential step to better understand the 
function of Aβ and its implication in AD. Schmitt-Ulms et al. recently performed an extensive 
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screening of proteins that bound to Aβ oligomers in human brain extracts.18 From over 50 
proteins detected, somatostatin (SST14) stood out for delaying Aβ aggregation and binding 
specifically to Aβ oligomers. To the best of our knowledge, the aforementioned work 
represents the largest Aβ monomeric and oligomeric in vivo interactome performed so far. The 
authors suggested that further investigations should be performed to improve the understanding 
of the SST14-Aβ interaction. In the present work, we used well established biophysical 
techniques to assess whether the specific Aβ oligomer binder, somatostatin-14 (SST14) bound 
to the βPFOAβ(1-42) tetramer. 
SST14 is a cyclic tetradecapeptide that is produced in neuroendocrine cells in the hypothalamus 
as well as in other tissues, including pancreas, intestinal tract and regions of the central nervous 
system.19,20 In a clinical context, SST14 is the neuropeptide most highly depleted in both the 
brain and cerebrospinal fluid (CSF) of AD patients.21,22 The relation to AD was further 
described by the work of Saido et al. as they found that SST14 regulates the metabolism of Aβ 
in the brain through the modulation of neprilysin which catalyses its proteolytic degradation.23 
Moreover, a positive correlation between SST14 and Aβ(1-42) levels was established in the 
CSF of elderly patients with mild cognitive impairment.24 Undoubtedly, previous work in the 
literature has established a strong link between SST14, Aβ and AD. Therefore, studying the 
potential interaction between SST14 and βPFOAβ(1-42) tetramer could deliver evidence to better 
understand the role of SST14 in the context of AD and point towards the relevance of βPFOAβ(1-




SST14 coelutes with βPFOAβ(1-42) tetramers 
We initially relied on size exclusion chromatography (SEC)25-27 to characterize the potential 
interaction between SST14 and βPFOAβ(1-42) tetramer in a membrane mimicking environment. 
As control samples, we followed the evolution of βPFOAβ(1-42) tetramer formation and SST14 
independently, following its incubation in the dodecyl phosphocholine (DPC) solution used as 
a membrane mimicking environment. Analysis of both samples showed that βPFOAβ(1-42) 
tetramers and SST14 eluted, respectively, at 13.5 mL and 17.5 mL (Supporting information; 
Figure S2A, B). In the case of the SST14 sample, its evolution over time revealed the 
appearance of wide peaks near the void volume, which were attributed to aggregated forms as 
previously reported for this peptide.28 Coincubation of Aβ(1-42) with SST14 under conditions 
that lead to βPFOAβ(1-42) tetramer formation resulted in an increase of 65% of the area under the 
peak assigned to βPFOAβ(1-42) tetramers (Figure 1A). Such a change could be explained either 
due to an increase in the formation of βPFOAβ(1-42) tetramer or the binding of SST14. 
Interestingly, we did not observe precipitates when both peptides were coincubated suggesting 
that the interaction between them increased the stability of SST14 in a membrane-mimicking 
environment. To assess whether binding occurred specifically during βPFOAβ(1-42) tetramer 
formation, we first incubated Aβ(1-42) alone for 24 h under conditions that lead to βPFOAβ(1-
42) tetramer formation and then added SST14. Analysis of this sample by SEC resulted in a 20% 
increase of the area under the peak assigned to βPFOAβ(1-42) tetramer (Supporting information, 
Figure S2D). This result suggested that SST14 binding was not exclusively occurring during 
βPFOAβ(1-42) tetramer formation but also when putting in contact the two binding partners after 




SST14 interacts with the Aβ(1-42) tetramer at a 2:1 ratio  
To further study the interaction between βPFOAβ(1-42) tetramer and SST14, we used isothermal 
titration calorimetry (ITC) to measure the heat exchange and obtain information about the 
energetic profile of the binding event. Titration of SST14 to the βPFOAβ(1-42) tetramer showed 
an exothermic interaction with a KD of ~40 µM and a stoichiometry of approximately 2:1 
(SST14 to βPFOAβ(1-42) tetramer) (Figure 1B, C). Such a binding ratio would indeed be in 
agreement with the symmetric structure of the βPFOAβ(1-42) tetramer. However, we could not 
exclude the possibility of SST14 interacting with remaining monomeric Aβ(1-42) in the 
sample.  
To better understand the specificity and stoichiometry of the interaction we analyzed the 
sample using native mass spectrometry (MS). This technique uses non-denaturing conditions 
to prepare the sample and soft ionization methods (such as electrospray ionization (ESI)) to 
preserve the non-covalent interactions within (βPFOAβ(1-42) tetramer) and between (βPFOAβ(1-
42) tetramer-SST14) molecular complexes.
29,30 To prepare the βPFOAβ(1-42) tetramer sample for 
MS analysis, we used lauryldimethylamine N-oxide (LDAO) instead of DPC to mimic the 
membrane environment as this detergent also supports βPFOAβ(1-42) tetramer formation and is 
compatible with MS analysis.31 Direct infusion of the resulting sample using nanoESI-MS 
delivered a clean spectrum displaying four consecutive charge states for the tetramer (+3, +4, 
+5 and +6) confirming that it was the major species in the sample (Figure 2A; Supporting 
information, Table S2). Infusion of a βPFOAβ(1-42) tetramer sample prepared in the presence of 
SST14 revealed consecutive charge states that were assigned to one (+3, +4 and +5) and two 
(+4, +5 and +6) SST14 molecules bound to the βPFOAβ(1-42) tetramer (Figure 2B; Supporting 
information, Table S2). Both ITC (Figure 1C) and native MS (Figure 2B) data pointed towards 
a 2:1 ratio for SST14 and βPFOAβ(1-42) tetramer interaction. Moreover, we did not observe any 
consecutive charge states corresponding to monomeric Aβ(1-42) bound to one or two SST14 
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molecules in agreement with SST14 binding specifically to oligomeric forms of Aβ 
(Supporting information; Figure S3, Table S1). 
SST14 binds to the flexible edges of the Aβ(1-42) tetramer 
The results obtained by SEC indicated that the binding event was stable over 24 h in the 
membrane-mimicking environment (Supporting information, Figure S2C), which encouraged 
us to further study the interaction by solution NMR. We therefore decided to pursue a deeper 
characterization by titrating SST14 into a 15N-βPFOAβ(1-42) tetramer sample and perform 2D 
[1H,15N]-SOFAST-HMQC experiments over time. The βPFOAβ(1-42) tetramer consists of a six-
stranded β-sheet comprising two types of Aβ(1-42) subunits referred to orange and green, 
respectively (Supporting information, Figure S1). The orange subunit contributes with two β-
strands (β1 and β2) and the green subunit contributes with one β-strand (β3) and a small α-
helix (α1).17 
The spectrum for βPFOAβ(1-42) tetramer displayed a well-dispersed set of signals as previously 
reported for this sample (Figure 3).16 Upon addition of SST14 to the NMR sample, several 
changes in chemical shifts were observed in the resulting spectrum indicating that SST14 
bound to βPFOAβ(1-42) tetramer. Indeed, specific shift changes in residues V12, F20, V24 G29, 
V40 and A42 of the orange subunit and in residues V12, V18, A21, E22, D23, G29, I41 and 
A42 of the green subunit of the βPFOAβ(1-42) tetramer were observed (Figure 4A; Supporting 
information, Figure S4; Source data 1). Chemical Shift Perturbations (CSPs) were considered 
significant if the values were greater than one standard deviation (𝜎) of the Euclidean chemical 
shift change represented as a grey dashed line (Figure 4A, Source data 1).32 Both the 
observation of smooth peak migrations between the free and bound states, and the derivation 
of koff rates using the maximum change in chemical shift, indicated that somatostatin binding 
occurred in the fast-exchange regime (Figure 3C).32,33 KD rates were determined for each 
clearly tractable residue by fitting the change in chemical shift as a function of the ligand 
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concentration. The tightest binding residues (Y10, F20) exhibited KD’s of ~35 and ~52 µM, 
respectively. 
The CSPs induced by SST14 were represented in the βPFOAβ(1-42) tetramer 3D structure (PDB 
code 6RHY) where the amide protons of the affected residues are represented as red spheres 
(Figure 4B). The affected residues showed to be close in space and defined a specific binding 
site within the tetramer structure. These CSPs were used to perform driven docking of SST14 
with the βPFOAβ(1-42) tetramer structure using the high ambiguity driven docking approach 
(HADDOCK).34 The best-scoring structural clusters that we obtained suggested a binding 
mode of SST14 in the βPFOAβ(1-42) tetramer where the peptide interacted with the flexible edges 
of the tetramer and interestingly also tightly with the alpha helix of the green subunit (Figure 
4C). 
The binding site defined in our study, enabled us to rationalize the specificity of the interaction 
between both entities since the spatial distribution of the residues in the βPFOAβ(1-42) tetramer 
is completely different to that of monomeric Aβ(1-42). The localization of the site was also in 
accordance with the 2:1 stoichiometry of the binding observed by ITC and native MS. Indeed, 
the symmetric topology of the tetramer contains two possible binding sites in the superior and 




In summary, our findings show that SST14 binds to βPFOAβ(1-42) tetramers with an affinity in 
the low micromolar range. Native MS experiments prove the binding to be specific for this 
oligomeric form with a 2:1 (SST14 to βPFOAβ(1-42) tetramer) stoichiometry, in accordance with 
ITC data. Our NMR experiments reveal two symmetric binding sites near the flexible ends of 
the tetramer. Restraint-driven in silico docking enables us to propose a binding mode of SST14 
to the tetramer structure. Altogether, we conclude that SST14, an in vivo binder to Aβ 
oligomers,18 specifically binds to βPFOAβ(1-42) tetramer. 
We observed an important difference when comparing our results with previously reported 
work on the binding of SST14 to soluble oligomers of Aβ(1-42).18 Indeed, work by Schmitt-
Ulms and collaborators postulated that SST14 did not bind to Aβ(17-42) oligomers which led 
them to conclude that the N-terminus was involved in the binding site. Our data, on the 
contrary, suggests that residues 18-29 are mainly involved in the binding with special emphasis 
on the ones forming the short alpha helix, residues L17 to F20. We recently showed that while 
Aβ(1-42) incorporates both as the orange and green subunit in the βPFOAβ(1-42) tetramer 
arrangement, Aβ(17-42) only incorporates as the green subunit,17 which prevents Aβ(17-42) to 
form βPFOAβ(1-42) tetramer by itself. Thus, for βPFOAβ(1-42) tetramer to form it is required that 
at least 50% of the peptides contain the N-terminus. These results evidence that using shortened 
versions of proteins can have a huge impact in protein self-assembly and structure. Moreover, 
work by Schmitt-Ulms et al. was performed on soluble oligomers while ours on a membrane-
associated oligomer. Therefore, the binding to SST14 may be different for each oligomer type. 
The authors also emphasized the importance of W8 of SST14 for the binding to occur. Indeed, 




Whilst our CSP-driven docking did not converge to a singular configuration for the SST14: 
βPFOAβ(1-42) tetramer interaction, a frequent observation across the best performing poses was 
that SST14 docks into the concave interior at the solvent-exposed edges of the βPFOAβ(1-42) 
tetramer (Figure 4C, Figure S5). In many of our calculated models, W8 of SST14 was found 
to interact with the hydrophobic residues of the βPFOAβ(1-42) tetramer, suggesting that W8 of 
SST14 could possibly mediate an interaction with the membrane-associated Aβ(1-42) tetramer. 
In the AD context, the critical role of SST14 in the metabolism of Aβ(1-42) through the 
regulation of neprilysin23 inevitably points towards the potential degradation of oligomeric 
forms of Aβ(1-42). Two important conclusions of the work by Saido and collaborators are the 
location of the SST14-neprylisin interaction situated near or in the cellular membrane and the 
fact that somatostatin-regulated neprilysin activity selectively depleted Aβ(1-42) but not Aβ(1-
40). Interestingly, the aforementioned facts also apply to βPFOAβ(1-42) tetramer since it is able 
to incorporate into membranes17 and is exclusively formed by Aβ(1-42) but not Aβ(1-40).16 
Proteolytic activities are tightly controlled biological processes that can be regulated at 
different levels such as through the formation of an activation complex.36 Therefore, we cannot 
exclude that binding of SST14 to the βPFOAβ(1-42) tetramer could induce its degradation.  
In the present study, we show at a structural level how SST14, which has been reported to bind 
to Aβ oligomers in human brain extracts, also binds to βPFOAβ(1-42) tetramer. We think these 
results strengthen the relation of SST14 with the amyloid cascade and due to the clear 
implication of SST14 in AD, it positions βPFOAβ(1-42) tetramer as relevant oligomer form of Aβ 
and as a potential target for AD. 
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Figures and Figure Legends 
 
 
Figure 1. SST14 binding to βPFOAβ(1-42) tetramer assessed by SEC and ITC. (A) SEC elution profile for 
βPFOAβ(1-42) tetramer after 24 hours of its formation in the absence (blue) and in the presence of SST14 
(red). The peaks have been labeled with the elution volume of βPFOAβ(1-42) tetramer and SST14. (B) ITC 
thermogram (top) and analysis of the fitted binding isotherm (bottom) for βPFOAβ(1-42) tetramer titrated 
with SST14. Standard deviation values were obtained from three independent replicates. (C) 








Figure 2. SST14 binding to βPFOAβ(1-42) tetramer assessed by native MS. (A) Electrospray ionization 
MS (ESI-MS) spectrum of βPFOAβ(1-42) tetramer (150 μM Aβ(1-42), 7.2 mM LDAO, 200 mM 
Ammonium Carbonate, pH 9.0 incubated for 24 hours). (B) ESI-MS spectrum of βPFOAβ(1-42) tetramer 
coincubated with SST14 (150 μM Aβ42, 150 μM SST14, 7.2 mM LDAO, 200 mM Ammonium 
Carbonate, pH 9.0 incubated for 24 hours). Charge states corresponding to SST14; Aβ(1-42) monomer, 
dimer, trimer, and tetramer are indicated with schematic drawings and labelled, respectively, in red, 




Figure 3. NMR titration of SST14 to βPFOAβ(1-42) tetramer. (A) Two-dimensional [15N, 1H]-SOFAST-
HMQC spectra of βPFOAβ(1-42) tetramer (230 μM Aβ(1-42), 7.71 mM d38-DPC, 10 mM d12-Tris·DCl, 
pH 8.5) alone (blue) and in the presence of 17 equivalents of SST14 (red). (B) Fitted saturation curves 
of residues F19, F20 and A21 during SST14 titration with their respective calculated KD. (C) Close-up 
view of residue F19 from the titration in the presence of 0 (blue), 2 (yellow), 5 (orange), 10 (coral) and 





Figure 4. Binding site of SST14 to βPFOAβ(1-42) tetramer. (A) Representation of the CSP of the residues 
within the orange and green subunits of the βPFOAβ(1-42) tetramer induced by the presence of SST14. 
The grey dashed line indicates the threshold dictated by the standard deviation (σ). Source data are 
provided in Source data 1. (B) Representation of the residues affected by chemical shift changes (red 
spheres) in the presence of SST14 within the 3D structure of the βPFOAβ(1-42) tetramer (PDB code 
6RHY). (C) Best-ranked structure proposing a binding mode of SST14 (cyan, PDB code 2MI1) with 
βPFOAβ(1-42) tetramer (orange and green). Residues introduced as ambiguous interaction restraints 
(AIRs) are colored in red. 
